Millennium Research Group Analyst Available to Comment on a Recent Study’s Findings of Unnecessary Implantation of Defibri

TORONTO--(BUSINESS WIRE)-- Millennium Research Group (MRG) Analyst, Julie McLaughlin, is available to comment on the recent study by Duke University that suggests 1 in 5 implantable cardioverter-defibrillators are unnecessarily implanted.

Implantable cardioverter-defibrillators include single- and dual-chamber implantable cardioverter-defibrillators and are used to treat rapid heart rates and in the primary prevention of sudden cardiac arrest. These devices restore normal sinus rhythm through a series of high- or low-energy electric impulses. Though dependent on manufacturer, programming, and use, implantable cardioverter-defibrillators typically last up to 8 years.

In an analysis of the National Cardiovascular Data Registry’s ICD Registry, published in the January 5, 2011 edition of the Journal of the American Medical Association, researchers at Duke University found that 22.5% of patients who received an implantable cardioverter-defibrillator in the United States from January 2006 to June 2009 did not meet the guidelines set out by the American Heart Association, American College of Cardiology, European Society of Cardiology, and Heart Rhythm Society.

MRG Vascular Analyst, Julie McLaughlin, is available to offer extensive expertise on this study. Ms. McLaughlin can comment on:

  • How the results of this study might impact a physician’s decision to implant an implantable cardioverter-defibrillator
  • The potential impact of this study on the implantable cardioverter-defibrillator market
  • The issue of higher rates of non–evidence-based implantation volumes for nonelectrophysiologists, and potential actions that could help address this disparity

“Implantable cardioverter-defibrillators are forecasted to grow at a faster rate than single- and dual-chamber pacemakers; however, this study has the potential to dampen growth of the implantable cardioverter-defibrillator market if physicians reduce their implantation volumes based on the study results,” says Ms. McLaughlin. “The results of the study must be interpreted carefully, as the majority of implantations that were considered to be “non–evidence-based” were given that label because they were implanted too soon—post initial heart failure diagnosis or post myocardial infarction—than the guidelines recommend. As a result of the study findings, some physicians could delay the timing of their implantation to remain in accordance with the guidelines. Whether this will alter overall implantation volumes remains to be seen.”

To arrange an interview with Ms. McLaughlin, please contact Amy Krohn at 416-364-7776 ext. 101 or [email protected].

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Millennium Research Group
Amy Krohn, 416-364-7776 ext. 101
[email protected]
or
Decision Resources Inc.
Chris Comfort, 781-993-2597
[email protected]

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Medical Devices

MEDIA:

Logo
 Logo

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.